MA46743A - Acides propioniques à substitution en position 3 en tant qu'inhibiteurs d'intégrine alpha v - Google Patents

Acides propioniques à substitution en position 3 en tant qu'inhibiteurs d'intégrine alpha v

Info

Publication number
MA46743A
MA46743A MA046743A MA46743A MA46743A MA 46743 A MA46743 A MA 46743A MA 046743 A MA046743 A MA 046743A MA 46743 A MA46743 A MA 46743A MA 46743 A MA46743 A MA 46743A
Authority
MA
Morocco
Prior art keywords
inhibitors
integrin alpha
propionic acids
acids substituted
substituted
Prior art date
Application number
MA046743A
Other languages
English (en)
Inventor
Palanikumar Balasubramanian
Rita Civiello
Pratik Devasthale
Suresh Dhanusu
Leatte R Guernon
Xiaojun Han
Swanee E Jacutin-Porte
Michael F Parker
Kumaravel Selvakumar
Xiang-Yang Ye
Guohua Zhao
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA46743A publication Critical patent/MA46743A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA046743A 2016-11-08 2017-11-07 Acides propioniques à substitution en position 3 en tant qu'inhibiteurs d'intégrine alpha v MA46743A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662418848P 2016-11-08 2016-11-08

Publications (1)

Publication Number Publication Date
MA46743A true MA46743A (fr) 2019-09-18

Family

ID=60409432

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046743A MA46743A (fr) 2016-11-08 2017-11-07 Acides propioniques à substitution en position 3 en tant qu'inhibiteurs d'intégrine alpha v

Country Status (28)

Country Link
US (2) US10968219B2 (fr)
EP (1) EP3538525B1 (fr)
JP (1) JP7097358B2 (fr)
KR (1) KR102505629B1 (fr)
CN (1) CN110167935B (fr)
AR (1) AR110153A1 (fr)
AU (1) AU2017359023B2 (fr)
CA (1) CA3042707A1 (fr)
CL (1) CL2019001264A1 (fr)
CO (1) CO2019005824A2 (fr)
DK (1) DK3538525T3 (fr)
EA (1) EA038164B1 (fr)
ES (1) ES2925173T3 (fr)
HR (1) HRP20220990T1 (fr)
HU (1) HUE059708T2 (fr)
IL (1) IL266473B (fr)
LT (1) LT3538525T (fr)
MA (1) MA46743A (fr)
MX (1) MX2019005244A (fr)
MY (1) MY199931A (fr)
PE (1) PE20191647A1 (fr)
PL (1) PL3538525T3 (fr)
PT (1) PT3538525T (fr)
RS (1) RS63483B1 (fr)
SI (1) SI3538525T1 (fr)
TW (1) TWI763733B (fr)
WO (1) WO2018089353A1 (fr)
ZA (1) ZA201903665B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
MA46744A (fr) * 2016-11-08 2019-09-18 Bristol Myers Squibb Co Composés mono et spirocycliques contenant du cyclobutane et de l'azétidine en tant qu'inhibiteurs de l'intégrine alpha v
MA46746A (fr) * 2016-11-08 2019-09-18 Bristol Myers Squibb Co Amides d'azole et amines en tant qu'inhibiteurs d'intégrine alpha v
EA038164B1 (ru) * 2016-11-08 2021-07-16 Бристол-Маерс Сквибб Компани 3-замещенные пропановые кислоты в качестве ингибиторов интегрина v
JP2020504120A (ja) 2016-12-29 2020-02-06 セントルイス ユニバーシティ インテグリンアンタゴニスト
EP3760202A1 (fr) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
RU2769702C2 (ru) 2017-02-28 2022-04-05 Морфик Терапьютик, Инк. Ингибиторы интегрина avb6
EP4086254A1 (fr) 2018-08-29 2022-11-09 Morphic Therapeutic, Inc. Inhibiteurs d'intégrine
CA3115830C (fr) 2018-10-30 2023-09-12 Gilead Sciences, Inc. Composes pour inhibition de l'integrine .alpha.4.beta.7
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CN112969687A (zh) 2018-10-30 2021-06-15 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
CN109824495B (zh) * 2019-02-02 2022-12-09 盐城师范学院 一种新型偶联反应在制备碳-碳键结构化合物中的应用
CN114222730A (zh) 2019-08-14 2022-03-22 吉利德科学公司 用于抑制α4β7整合素的化合物
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451790A1 (fr) * 1990-04-12 1991-10-16 Hoechst Aktiengesellschaft 2-isoxazolines et isoxazoles 3,5-disubstitués, procédé pour leur préparation,médicaments les contenant et leur utilisation
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
CA2309204A1 (fr) 1997-11-26 1999-06-03 Dupont Pharmaceuticals Company 1,3,4-thiadiazoles et 1,3,4-oxadiazoles utilises comme antagonistes de .alpha.v.beta.3
WO1999030709A1 (fr) * 1997-12-17 1999-06-24 Merck & Co., Inc. Antagonistes du recepteur de l'integrine
AU748621B2 (en) * 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
WO2002060438A1 (fr) 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Indoles substitues et utilisation de ceux-ci comme antagonistes d'integrine
US20050043344A1 (en) * 2002-12-20 2005-02-24 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists derivatives
EP1572691A1 (fr) * 2002-12-20 2005-09-14 Pharmacia Corporation Composés de pyrazole en tant qu' 'antagonsites des récepteurs de l'integrine
WO2006108040A1 (fr) 2005-04-05 2006-10-12 Janssen Pharmaceutica, N.V. Indoles substitues et leur utilisation en tant qu'antagonistes de l'integrine
TW200800999A (en) * 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
AR059224A1 (es) 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
JP2009539815A (ja) * 2006-06-09 2009-11-19 アストラゼネカ アクチボラグ 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物
WO2008125811A1 (fr) * 2007-04-11 2008-10-23 Astrazeneca Ab DÉRIVÉS DE N-[HÉTÉROARYLCARBONYL]-S-THIÉNYL-L-ALANINE EN TANT QU'ANTAGONISTES DE L'INTÉGRINE α5β1
JP2013503834A (ja) 2009-09-04 2013-02-04 ビーエーエスエフ ソシエタス・ヨーロピア １−フェニルピラゾールの製造方法
US9556201B2 (en) 2009-10-29 2017-01-31 Glaxosmithkline Llc Bicyclic pyridines and analogs as sirtuin modulators
ITFI20100019A1 (it) 2010-02-12 2011-08-13 Univ Firenze Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori.
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3925959A1 (fr) 2015-02-19 2021-12-22 OcuTerra Therapeutics, Inc. Dérivés fluorés de l'acide 3-(2-oxo-3-(3-(5,6,7,8-tétrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoïque et leurs utilisations
AU2016228852A1 (en) 2015-03-10 2017-10-19 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
EA038164B1 (ru) * 2016-11-08 2021-07-16 Бристол-Маерс Сквибб Компани 3-замещенные пропановые кислоты в качестве ингибиторов интегрина v

Also Published As

Publication number Publication date
JP2019537594A (ja) 2019-12-26
EP3538525A1 (fr) 2019-09-18
PT3538525T (pt) 2022-08-16
HUE059708T2 (hu) 2022-12-28
PE20191647A1 (es) 2019-11-07
PL3538525T3 (pl) 2022-09-12
TW201823244A (zh) 2018-07-01
TWI763733B (zh) 2022-05-11
IL266473B (en) 2022-06-01
US11884661B2 (en) 2024-01-30
WO2018089353A1 (fr) 2018-05-17
EA201991122A1 (ru) 2019-10-31
US10968219B2 (en) 2021-04-06
AR110153A1 (es) 2019-02-27
MX2019005244A (es) 2019-08-05
EA038164B1 (ru) 2021-07-16
US20190263808A1 (en) 2019-08-29
AU2017359023B2 (en) 2021-12-09
SI3538525T1 (sl) 2022-09-30
KR20190073554A (ko) 2019-06-26
US20210188847A1 (en) 2021-06-24
EP3538525B1 (fr) 2022-06-22
ZA201903665B (en) 2022-12-21
CN110167935B (zh) 2022-05-27
AU2017359023A1 (en) 2019-06-20
IL266473A (en) 2019-07-31
CA3042707A1 (fr) 2018-05-17
MY199931A (en) 2023-11-29
DK3538525T3 (da) 2022-08-29
CL2019001264A1 (es) 2019-09-13
JP7097358B2 (ja) 2022-07-07
RS63483B1 (sr) 2022-09-30
ES2925173T3 (es) 2022-10-14
CN110167935A (zh) 2019-08-23
CO2019005824A2 (es) 2019-06-11
KR102505629B1 (ko) 2023-03-02
HRP20220990T1 (hr) 2022-11-11
LT3538525T (lt) 2022-09-26

Similar Documents

Publication Publication Date Title
MA46743A (fr) Acides propioniques à substitution en position 3 en tant qu'inhibiteurs d'intégrine alpha v
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA54546A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA46746A (fr) Amides d'azole et amines en tant qu'inhibiteurs d'intégrine alpha v
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA46745A (fr) Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
MA40775A (fr) Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA53399A (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA53352A (fr) Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
MA42032A (fr) Acides 3-aryl-4-amido-bicyclo [4,5,0]hydroxamiques en tant qu'inhibiteurs de hdac
MA52123A (fr) Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2
DK3532029T3 (da) Flydende farmaceutisk sammensætning
MA46608A (fr) Formulation liposomale destinée à être utilisée dans le traitement du cancer
MA47736A (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
MA49841A (fr) Carboxamides utilisées en tant qu'inhibiteurs de protéase spécifique de l'ubiquitine
MA43685A (fr) Solutions aqueuses d'acides aminés n-acylés
MA45159A (fr) Polypeptides d'hémagglutinine d'influenza modifiés
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1
CO2017000211A2 (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
ITUA20161350A1 (it) Dispositivo di visione per realta' aumentata